Literature DB >> 2764537

Comparison of N-methylthiotetrazole dispositions in healthy volunteers following single intravenous doses of moxalactam, cefoperazone, and cefotetan.

L S Welage1, L G Hejmanowski, J H Wilton, C Walawander, D Rigan, J S Williams, J J Schentag.   

Abstract

The N-methylthiotetrazole side chain (NMTT) that is present on several cephalosporins has been implicated in the development of antibiotic-associated hypoprothrombinemia. A randomized three-way crossover trial was conducted to compare the release of the NMTT side chain from three NMTT-containing antibiotics. Single 2-g doses of moxalactam, cefoperazone, and cefotetan were given, followed by serial blood and urine sampling. The concentrations of the parent compound and the NMTT side chain in plasma, urine, and the reconstituted antibiotic solution were determined by high-pressure liquid chromatography. Peak NMTT concentrations ranged from 0.42 to 16.50 micrograms/ml and were significantly higher after moxalactam administration than after cefoperazone or cefotetan administration (P less than 0.01). The NMTT trough concentrations (12.5 h) ranged from nondetectable to 2.47 micrograms/ml and tended to be greater following cefoperazone administration. The amounts of NMTT administered (e.g., the amount in the reconstituted antibiotic solution) were 25.8 +/- 1.4, 15.2 +/- 0.9, and 22.1 +/- 3.0 mg following moxalactam, cefoperazone, and cefotetan administration, respectively (P less than 0.01). In contrast, urinary recoveries of NMTT were 57.4 +/- 26.2, 73.6 +/- 44.3, and 29.7 +/- 22.9 mg following moxalactam, cefoperazone, and cefotetan, respectively. The amount of NMTT formed in vivo and excreted unchanged, as assessed by subtracting in vitro NMTT formation from NMTT urinary recovery, was significantly higher after cefoperazone than after moxalactam or cefotetan administration (P less than 0.05). The discrepancy between in vitro NMTT production (moxalactam > cefotetan > cefoperazone) and the amount of NMTT formed in vivo and excreted unchanged (cefoperazone > moxalactam > cefotetan) demonstrated that the in vivo production of NMTT is dependent on the disposition of the parent cephalosporin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2764537      PMCID: PMC284245          DOI: 10.1128/AAC.33.6.857

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Effect of N-methyl-thiotetrazole on vitamin K epoxide reductase.

Authors:  K A Creedon; J W Suttie
Journal:  Thromb Res       Date:  1986-10-15       Impact factor: 3.944

2.  Effect of N-methyl-thiotetrazole on rat liver microsomal vitamin K-dependent carboxylation.

Authors:  J W Suttie; J A Engelke; J McTigue
Journal:  Biochem Pharmacol       Date:  1986-07-15       Impact factor: 5.858

3.  N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.

Authors:  J J Lipsky
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

4.  Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins.

Authors:  H Bechtold; K Andrassy; E Jähnchen; J Koderisch; H Koderisch; L S Weilemann; H G Sonntag; E Ritz
Journal:  Thromb Haemost       Date:  1984-07-29       Impact factor: 5.249

5.  Effects of latamoxef and methyltetrazolethiol on gamma-glutamylcarboxylase activity.

Authors:  K Uchida; T Ishigami; T Komeno
Journal:  Jpn J Pharmacol       Date:  1984-07

6.  The effects of 1-methyl-5-thiotetrazole in a rat liver vitamin K-dependent carboxylase assay.

Authors:  G F Smith; J L Sundboom
Journal:  Thromb Res       Date:  1984-03-15       Impact factor: 3.944

7.  Mechanism of the inhibition of the gamma-carboxylation of glutamic acid by N-methylthiotetrazole-containing antibiotics.

Authors:  J J Lipsky
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

8.  Kinetics and action of N-methylthiotetrazole in volunteers and patients. Population-based clinical comparisons of antibiotics with and without this moiety.

Authors:  J J Schentag; L S Welage; J S Williams; J H Wilton; M H Adelman; D Rigan; T H Grasela
Journal:  Am J Surg       Date:  1988-05-31       Impact factor: 2.565

9.  Pharmacokinetics and protein binding of cefamandole and its 1-methyl-1 H-tetrazole-5-thiol side chain in subjects with normal and impaired renal function.

Authors:  G R Aronoff; R L Wolen; B D Obermeyer; H R Black
Journal:  J Infect Dis       Date:  1986-06       Impact factor: 5.226

10.  Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycin.

Authors:  J G Baxter; D A Marble; L R Whitfield; P B Wels; P Walczak; J J Schentag
Journal:  Ann Surg       Date:  1985-01       Impact factor: 12.969

View more
  5 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

2.  Pharmacokinetic differences between the epimers of cefotetan disodium after single intravenous injection in healthy Chinese volunteers.

Authors:  Meng-xiang Su; Min-hong Liu; Bin Di; Li-li Huang; Yuan Jiang; Peng-cheng Ma; Tai-jun Hang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-09-14       Impact factor: 2.441

3.  Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan, and cefmetazole.

Authors:  L S Welage; M T Borin; J H Wilton; L G Hejmanowski; P B Wels; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  Role of prophylactic vitamin K in preventing antibiotic induced hypoprothrombinemia.

Authors:  Farookh Aziz; Prashant Patil
Journal:  Indian J Pediatr       Date:  2014-10-10       Impact factor: 1.967

5.  The Association Between Cephalosporin and Hypoprothrombinemia: A Systematic Review and Meta-Analysis.

Authors:  Gi Hyue Park; Seungyeon Kim; Min Soo Kim; Yun Mi Yu; Gun Hee Kim; Jeong Sang Lee; Euni Lee
Journal:  Int J Environ Res Public Health       Date:  2019-10-16       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.